CYAD - Dosing underway in Celyad's early-stage colorectal cancer study with CAR T candidate

Celyad Oncology (CYAD) has dosed the first patient in the expansion cohort of the Phase 1 alloSHRINK trial evaluating CYAD-101, its allogeneic T cell receptor inhibitory molecule-based, non-gene edited CAR T candidate for the treatment of refractory metastatic colorectal cancer. The study is assessing the safety and clinical activity of three consecutive administrations of CYAD-101 every two weeks administered concurrently with preconditioning chemotherapy.In the expansion cohort of the trial, CYAD-101 will be administered at the recommended dose of one billion cells per infusion concurrently with FOLFIRI (combination of 5-fluorouracil, leucovorin and irinotecan) chemotherapy.

For further details see:

Dosing underway in Celyad's early-stage colorectal cancer study with CAR T candidate